表紙
市場調査レポート

アルテプラーゼの中国市場

Investigation Report on China Alteplase Market, 2010-2019

発行 China Research and Intelligence 商品コード 338985
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
アルテプラーゼの中国市場 Investigation Report on China Alteplase Market, 2010-2019
出版日: 2015年09月07日 ページ情報: 英文 20 Pages
概要

アルテプラーゼは第2世代の血栓溶解剤で、プラズミノーゲンの活性化やフィブリンの溶解により血餅を溶解する機能を有しており、特に急性心筋梗塞の際に冠状動脈の詰まりを取り除くことができます。中国の場合、調査対象病院での売上高は、2005年の1200万人民元から、2014年には4000万人民元以上と、16.3%の年平均成長率 (CAGR) で拡大しています。近年、中国では若年層の心血管疾患の患者数が増加していることから、アルテプラーゼなどの抗血餅薬の市場機会は非常に大きいと言えます。

当レポートでは、中国におけるアルテプラーゼの市場について分析し、ジドロゲステロンの特徴や認証状況、全体的な市場規模、企業別・剤形別の市場シェア、価格動向、主要メーカーのプロファイル、今後の市場成長の見通しなどについて調査・推計しております。

第1章 アルテプラーゼの関連概念

  • 適応症
  • 世界市場での販売状況

第2章 中国のアルテプラーゼ市場のプロファイル

  • 中国国内でのアルテプラーゼの特許申請・承認状況
  • 主要メーカー
  • 市場規模

第3章 中国国内のアルテプラーゼ販売額の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 アルテプラーゼの主要メーカーの市場シェア (過去5年間分)

  • 市場シェア (金額ベース)
  • 市場シェア (数量ベース)

第5章 中国国内でのアルテプラーゼの剤形 (過去5年間分)

  • 剤形別の市場シェア (金額ベース)
  • 剤形別の市場シェア (数量ベース)

第6章 中国の病院におけるアルテプラーゼの参照価格

  • Boehringer-Ingelheim AG (ドイツ)
  • Shandong Ahua Biopharmaceutical Co., Ltd

第7章 中国国内のアルテプラーゼの主要メーカー (過去5年間分)

  • Boehringer-Ingelheim AG (ドイツ)
  • Shandong Ahua Biopharmaceutical Co., Ltd

第8章 中国国内のアルテプラーゼ市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の予測

図表一覧

目次
Product Code: 1509314

As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery.

Plasmin working by resolving fibrous protein in clots takes up a small market share while plasminogen activator represented by alteplase developed by Genentech is the mainstream product in global market. In China, only Actilyse, a life-saving injection of Boehringer-Ingelheim AG with approved indications of acute myocardial infarction, (acute) pulmonary embolism and acute ischemic stroke is available. Having been approved by over 85 countries in the world, actilyse is marketed by Boehringer-Ingelheim AG in areas outside North America and Japan, by Genentech under the trade name of Activase since 1996 in the US and by Roche since 1999 in the Canada. Ever since its appearance, actilyse has been widely used to treat acute ischemic stroke.

According to CRI's market survey, the annual sales value of alteplase in sample hospitals rose from less than CNY 12 million in 2005 to over CNY 40 million in 2014 and CAGR during this period reached 16.3%. Boehringer-Ingelheim AG (Germany) and Shandong Ahua Biopharmaceutical Co., Ltd dominate the market with the former having the largest market share of over 90% for sales value in 2014.

Currently, the number of cardiovascular disease reports an increasing number of younger patients, high fatality and disability in China. According to the Report on Cardiovascular Diseases in China (2013), there are about 290 million people suffering from cardiovascular diseases. Since 2005, acute myocardial infarction has reported an increasing fatality and each year only 5% of 2.5 million patients per year can get treatment. Hence the vast market for anti-clotting drugs in China.

Readers can get at least the following information through this report:

  • market size of alteplase in China
  • competitive landscape of alteplase market in China
  • price of alteplase made by different enterprises in China
  • market outlook of alteplase in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-clotting drugs
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Alteplase

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Alteplase in China

  • 2.1. Patent and Approval Information of Alteplase in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Alteplase sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Alteplase Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Alteplase in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Alteplase in Chinese Hospitals in 2014

  • 6.1. Boehringer-Ingelheim AG (Germany)
  • 6.2. Shandong Ahua Biopharmaceutical Co., Ltd

7. Major Manufacturers of Alteplase in Chinese Market, 2010-2014

  • 7.1. Boehringer-Ingelheim AG (Germany)
  • 7.2. Shandong Ahua Biopharmaceutical Co., Ltd

8. Market Outlook of Alteplase in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Alteplase in China
  • Chart Alteplase Sales in China
  • Chart Sales Value of Alteplase in China, 2010-2014
  • Chart Sales Value of Alteplase in Some Regions in China, 2010-2014
  • Chart Sales Volume of Alteplase in China, 2010-2014
  • Chart Sales Volume of Alteplase in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Made by Shandong Ahua in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Alteplase Tablet in China, 2010-2014
  • Chart Price of Alteplase Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Alteplase Made by Shandong Ahua Biopharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top